Wall Street analysts expect Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to report sales of $8.51 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Conatus Pharmaceuticals’ earnings. The highest sales estimate is $10.00 million and the lowest is $6.13 million. Conatus Pharmaceuticals reported sales of $8.80 million in the same quarter last year, which indicates a negative year-over-year growth rate of 3.3%. The firm is expected to report its next earnings results on Wednesday, March 6th.
On average, analysts expect that Conatus Pharmaceuticals will report full year sales of $34.81 million for the current fiscal year, with estimates ranging from $32.30 million to $36.18 million. For the next year, analysts anticipate that the firm will report sales of $46.87 million, with estimates ranging from $25.32 million to $80.80 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that cover Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Thursday, November 1st. The biotechnology company reported ($0.15) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.15). The company had revenue of $7.67 million during the quarter, compared to the consensus estimate of $9.70 million. Conatus Pharmaceuticals had a negative net margin of 52.77% and a negative return on equity of 83.99%.
A number of hedge funds and other institutional investors have recently bought and sold shares of CNAT. Artal Group S.A. purchased a new stake in Conatus Pharmaceuticals during the third quarter worth about $2,900,000. BlackRock Inc. increased its holdings in Conatus Pharmaceuticals by 13.4% during the third quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock worth $9,419,000 after buying an additional 191,287 shares during the last quarter. Alambic Investment Management L.P. increased its holdings in Conatus Pharmaceuticals by 207.0% during the second quarter. Alambic Investment Management L.P. now owns 264,665 shares of the biotechnology company’s stock worth $1,133,000 after buying an additional 178,461 shares during the last quarter. Paloma Partners Management Co purchased a new stake in Conatus Pharmaceuticals during the second quarter worth about $547,000. Finally, LMR Partners LLP purchased a new stake in Conatus Pharmaceuticals during the second quarter worth about $311,000. Institutional investors and hedge funds own 35.09% of the company’s stock.
Shares of CNAT stock traded down $0.17 on Thursday, hitting $4.48. The stock had a trading volume of 281,958 shares, compared to its average volume of 643,661. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83. Conatus Pharmaceuticals has a 12-month low of $3.22 and a 12-month high of $7.95.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Read More: Correction
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.